Cyclic Peptide Synthesis for Drug Discovery: Uses, Benefits and Challenges

Life Sciences, Drug Discovery & Development, Fundamental Research,
  • Thursday, March 21, 2024

In 2023, peptide-based drugs continued to gain prominence, and three out of six new peptide drug approvals were for cyclic peptides due to their favorable drug properties, such as cell permeability, proteolytic stability and binding kinetics. Cyclic peptides, however, often result in challenging projects due to the difficulty of synthesis or time constraints.

This webinar focuses on the collaboration with a UK-based contract research organization (CRO), Charnwood Discovery, to understand the recent advances in peptide drug development. The session will specifically focus on cyclic peptides and the challenges involved in their manufacturing, handling and applications from a CRO’s perspective.

The experts will explore the nuances of cyclic peptide synthesis and how the CRO leverages state-of-the-art technology to enhance its capabilities to meet complex project requirements. Attendees will learn about the synthesis and cyclization of peptides, potential issues with ring strain and what to look for when working with unstable cyclic peptide, as well as approaches to understanding the structure–activity relationship (SAR) of a cyclic peptide and some issues in drug discovery. This session is ideal for anyone interested in cyclic peptide synthesis and its role in drug discovery.

Register for this webinar to understand the challenges and strategies for synthesizing cyclic peptides and understand its role in drug discovery.


Dr James Krupa, Charnwood Discovery

Dr. James Krupa, Principal Research Scientist, Charnwood Discovery

Dr. James Krupa is a Principal Research Scientist at Charnwood Discovery, a Contract Research Organisation in the UK. James’ career has been split between organic chemistry and peptide synthesis, beginning in the School of Chemistry at the University of Nottingham in the UK, where James earned his PhD in 2015 for his work on the development of fluorine MRI probes for imaging protease activity. James then went on to begin his industrial career, first in peptide chemistry at Pepceuticals, followed by a move to Charnwood Molecular, now Charnwood Discovery. James then went back into academia for a year with a Postdoc at the School of Medicine, University of Nottingham, developing Xenon MRI agents. In 2018, James returned to Charnwood Discovery where he leads a team of synthetic chemists working to meet his clients’ needs.

Message Presenter

Who Should Attend?

  • Scientists, Senior Scientists, Technical Leaders or Researchers interested in peptide or protein chemistry
  • PhD Candidates, Post-doctoral Researchers
  • Researchers involved in peptide therapeutics or peptide synthesis

What You Will Learn

  • Hints and tips for synthesis and cyclization of peptides
  • Issues with ring strain and what to look for/be aware of when working with cyclic peptides
  • Approaches to understanding the SAR of a cyclic peptide
  • Cyclic peptides and potential issues in drug discovery

Xtalks Partner

Gyros Protein Technologies

Gyros Protein Technologies enables peptide and bioanalytical solutions that help scientists increase biomolecule performance and productivity in research, drug discovery, pre-clinical and clinical development, and bioprocess applications. Our low to mid-scale peptide synthesizer platforms are the PurePep® Chorus, Symphony® X, and PurePep® Sonata®+. The PurePep® EasyClean (PEC™) technology complements the PurePep® portfolio with Kits and Services for peptide purification and modification.

These solutions and our chemistries deliver uncompromising purity, flexibility, and quality for discovery and pre-clinical studies of simple to complex multifunctional peptides up- and downstream. Proprietary high performance nanoliter-scale immunoassay platforms, Gyrolab® xPand, Gyrolab® xP workstation and Gyrolab xPlore™, are used by scientists in leading pharmaceutical, biotech, CRO, and CMO companies for bioanalytical applications such as pharmacokinetics/pharmacodynamics, immunogenicity, and quantitating bioprocess-related impurities. Our peptide and bioanalytical solutions accelerate your discovery, development, and manufacturing of safer biotherapeutics. Gyros Protein Technologies is part of the Biopharmaceutical Division of Mesa Laboratories, Inc.

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account